Company intelligence / Profile preview

UGH Pharma

Ownership: Private
Development stage: Other

Overview

UGH Pharma, Inc. is a preclinical-stage biotechnology company focused on developing neuroprotective peptide therapeutics for neurodegenerative and ischemic diseases. The company's lead asset is ND-13, a novel 20-amino acid cell-penetrating peptide derived from the DJ-1 (PARK7) protein. ND-13 is designed to protect cells against oxidative stress, neurotoxicity, and mitochondrial dysfunction by activating the Nrf2 pathway. The therapeutic candidate has demonstrated efficacy in preclinical animal models of Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), and focal ischemic stroke. UGH Pharma holds exclusive licensing rights to the DJ-1 peptide technology from Ramot at Tel Aviv University.

Therapeutic areas: Neurology
Modalities: PeptidesBiologic
Industry: Biotech

Drug pipeline

1 asset

ND-13

Preclinical

Partnerships

Ramot at Tel Aviv University

Beyond the preview

Go deeper on UGH Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UGH Pharma.